
HOME		SEARCH		RSS FEED		SUBSCRIBE

Search Results - db3xxx

22 Results

Sort By:

Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response

This CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated...

Published: 7/25/2024 | Inventor(s): Larry Anderson, Deborah Moore, Ralph Tripp

Keywords(s): bronchoilitis, CAUSED, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB3XXX, DB4XXX, DBXXXX, DISEASES, DXXXXX, IB3XXX, Infection, Inflammation, INFLAMMATORY, Methods, nitric oxide, OID-NCIRD-DVD, P, Pain, pain control, Prevention, Pulmonary, RESPONSE, RSV, RSV virus, SUBSTANCE, SUBSTANCE p, treatment, treatment methods, vasodilation, VASODILATOR, VAXXXX, VBXXXX, VDXXXX, VEXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Ophthalmology, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, TherapeuticArea > Oncology, Application > Consumer Products, Application > Therapeutics, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Vaccines, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Geriatrics

Stable, Early-stage Biomarker for Diagnosis of Bacillus anthracis Infection and Anthrax Vaccine Development

This invention comprises monoclonal antibodies, proteins, and related nucleic acid coding sequences that identify all or part of the antigenic anthrose oligosaccharide of Bacillus anthracis, the causative agent of anthrax toxicity in humans. It is imperative to identify virulent B. anthracis with speed and specificity, however there presently is substantial...

Published: 4/8/2024 | Inventor(s): Conrad Quinn, Geert-Jan Boons, Russell Carlson, Elke Saile

Keywords(s): Anthracis, ANTHROSE, antibodies, Bacillus, CDC Docket Import, CDC Docket Import NP, Cell, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DEXXXX, DXXXXX, Hybridoma, Lines, monoclonal, Recognizing, SACCHARIDE, VBXXXX, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Occupational Safety and Health, Application > Therapeutics, ResearchProducts > Antibodies, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, ResearchProducts > Research Equipment

Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics

CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax...

Published: 7/25/2024 | Inventor(s): Dennis Bagarozzi, Anne Boyer, Conrad Quinn, Jason Goldstein

Keywords(s): Activiating, Activity, Anthracis, Anthrax, AnthraxToxins, Bacillus, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DB3XXX, DB5XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX, Epitope, factor, INFECTIOUS, Lethal, MONITOR, MONITORING, Neutralize, Neutralizing, Region, REGULATING, SCREEN, screening, SERODIAGNOSIS, SERODIAGNOSTIC, Serologic, SEROLOGICAL, therapeutic, Therapeutic/Diagnostic, THERAPY, toxin, TOXIN-BINDING, Vaccine, VBXXXX, VETERINARY, Via, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo, Zoonotic

Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Occupational Safety and Health, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Therapeutics, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, Application > Research Materials, ResearchProducts > Antibodies, Application > Diagnostics

Intranasal Nebulizer with Disposable Drug Cartridge for Improved Delivery of Vaccines and Therapeutics

Intranasal delivery is a simple, inexpensive and needle-free route for administration of vaccines and therapeutics. This intranasal delivery technology, developed with Creare LLC., includes low-cost, disposable drug cartridges (DDCs) that mate with a durable hand-held device. The rechargeable-battery-powered device transmits ultrasonic energy to the...

Published: 7/25/2024 | Inventor(s): James Barry, Nabil Elkouh, Mark Bagley, Darin Knaus, Robert Trabka, Eric Friets, James Norris, Mark Papania

Keywords(s): AB1XXX, AB3FXX, AB3GXX, AB3XXX, AB4XXX, Able, ABXXXX, AC1XXX, ACXXXX, AEROSOL, AEROSOL-GENERATING, AEROSOLIZATION, Aerosolized, AEROSOLS, AXXXXX, BACTERIA, Bacterial, BACTERIAL VACCINES, CARTRIDGE, CDC, CDC Docket Import, CDC Docket Import CDC Prosecuting, Chamber, COOLING, DB1XXX, DB2XXX, DB3XXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DC2XXX, DC3XXX, DC4XXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, Delivery, DEVICE, Devices, Disposable, DRUG, Drug Delivery, DXXXXX, FUNGAL, HAND, Having, INSERT, Intranasal, Methods, NASAL, NEBULIZER, NIOSH-PRL, OID-NCIRD-DVD, PLATFORM, Platforms, Pulmonary, respiratory, Respiratory Diseases, respiratory INFECTION, System, SYSTEMS, therapeutic, therapeutic delivery, Vaccine, VACCINE DELIVERY, Vaccine Design, VACCINE DEVELOPMENT, VBXXXX, viral, viral vaccine, VJXXXX, VKXXXX, VLXXXX, VOXXXX, VPXXXX, WAXXXX, WFXXXX, WJXXXX, WKXXXX, WMXXXX, XDXXXX, YBXXXX, YCXXXX, YFXXXX

Category(s): Collaboration Sought > Licensing, Application > Occupational Safety and Health, Application > Medical Devices, Application > Diagnostics, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Dental, TherapeuticArea > Infectious Disease, TherapeuticArea > Endocrinology, TherapeuticArea > Cardiology, Application > Non-Medical Devices, TherapeuticArea > Ophthalmology, Application > Consumer Products, TherapeuticArea > Oncology

Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics

This Intranasal Dry Powder Inhaler (DPI), developed with Creare, Inc., allows low-cost delivery of powder vaccines. Nasal delivery has numerous advantages compared to traditional injected vaccines, including: 1) safe, needle-less administration by minimally-trained staff or patient; 2) better protection due to mucosal and cross-protection; and 3) decreased...

Published: 7/25/2024 | Inventor(s): James Barry, Darin Knaus, Edward Moynihan, Eric Friets, Mark Bagley, Mark Papania

Keywords(s): AB1XXX, AB3FXX, AB3GXX, ABXXXX, Agents, AXXXXX, BACTERIA, Bacterial, BACTERIAL VACCINES, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, Child safety device, CHILDHOOD, Children, DB1XXX, DB2XXX, DB3XXX, DB4AXX, DB4BXX, DB4XXX, DB5XXX, DBXXXX, DC1XXX, DC2XXX, DC3XXX, DC4XXX, DC5XXX, DC6XXX, DCXXXX, Delivery, delivery system, DEVELOPED, DEVELOPING, DEVICE, Devices, Disposable, DISPOSAL, Dry, DXXXXX, Field, Field-usable, FUNGAL, Intranasal, MEASLES, NASAL, Needle, OID-NCIRD-DVD, Portable, POWDER, Prevention, respiratory, SAFETY, SELF-ADMINISTRATION, Single-use, System, therapeutic delivery, treatment, VACCINATION, Vaccinations, VACCINE DELIVERY, vaccines, VBXXXX, viral vaccine, VJXXXX, VKXXXX, VLXXXX, VOXXXX, WAXXXX, WKXXXX, WMXXXX, XDXXXX, YBXXXX, YFXXXX

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, Application > Medical Devices, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Non-Medical Devices, Application > Consumer Products, Application > Therapeutics

Novel Targets to Prevent Borrelia burgdorferi Infection and Lyme Disease

B. burgdorferi-infected ticks can cause Lyme disease in mammalian hosts. This technology relates to the use of B. burgdorferi outer surface proteins (BBA64 and BBA66) as Lyme disease vaccine candidates. In vivo animal studies demonstrate these outer surface proteins inhibit tick-to-host B. burgdorferi transmission. Presently, there is no vaccine approved...

Published: 4/8/2024 | Inventor(s): Robert Gilmore

Keywords(s): BBA66, BORRELIA, BURGDORFERI, CDC Docket Import, CDC Docket Import CDC Prosecuting, COMPONENT, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DXXXXX, Gene, Infectivity, MAMMALIAN, Necessary, PATHOGEN, TICK, TRANSMISSION, Vector, Via

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Therapeutics, Application > Vaccines, Application > Diagnostics

Peptide Vaccines Against Group A Streptococci

This invention relates to synthetic immunoreactive peptides, which are portions of the M proteins of the most prevalent Group A Streptococcus (GAS) serotypes in the United States. These peptides may be useful in development of a flexible, multivalent GAS vaccine. They can be recognized by M type-specific antibodies and are capable of eliciting functional...

Published: 7/25/2024 | Inventor(s): George Carlone, Jacquelyn Sampson, Edwin Ades, Bernard Beall

Keywords(s): Against, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, GROUP, OID-NCIRD-DBD, Peptide, Streptococci, vaccines

Category(s): Collaboration Sought > Licensing, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

Method of Enhancing Opsonophagocytosis

This invention aims to bolster the human body's own mechanisms to fight infection by enhancing an innate immune response, opsonophagocytosis. The specific 24 amino acid sequence (P4) acts as a polymorphonuclear cell activator. P4 can be administered in vivo along with a disease's specific antibody to enhance systemic bacterial clearance, thus leading...

Published: 7/25/2024 | Inventor(s): GowriSankar Rajam, Sandra Steiner, George Carlone, Nikkol Atwell-Melnick Melnick, Jacquelyn Sampson, Joseph Martinez, Joseph Caba, Edwin Ades

Keywords(s): ANTIGEN, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DAXXXX, DB3XXX, DB5XXX, DBXXXX, DC1XXX, DC4XXX, DCXXXX, DXXXXX, ENHANCING, Epitopes, FUNCTIONAL, Listed LPM Surabian as of 4/15/2015, Methods, OID-NCIRD-DBD, Opsonophagocytosis, PATHOGEN, PNEUMONIAE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PsaA, RESPONSE, Streptococcus, THEREOF, USES

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease

Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities

Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Andrei Pomerantsev

Keywords(s): Anthracis, Anthrax, ATCC, Bacillus, Bacterial, BH460, DB3XXX, DBXXXX, DC4XXX, DC6XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, HOST, Improved, production, proteins, toxin, vaccines

Category(s): Collaboration Sought > Collaboration, Application > Vaccines, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Infectious Disease

Monoclonal Antibodies That React With the Capsule of Bacillus anthracis

Bacillus anthracis is the causative agent of anthrax and is surrounded by a polypeptide capsule of poly-gamma-D-glutamic acid (gammaDPGA). gammaDPGA is poorly immunogenic and has antiphagocytic properties. The bacterial capsule is essential for virulence. Antibodies to the capsule have been shown to enhance phagocytosis and killing of encapsulated...

Published: 7/25/2024 | Inventor(s): Robert Purcell, Rachel Schneerson, Joanna Kubler-kielb, Lily Zhongdong Dai, Zhaochun Chen

Keywords(s): Anthracis, Anthrax, antibodies, Autoimmune polyendocrinopathy syndrome, type 1, Bacillus, Capsule, chimeric, Chimpanzee/Human, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, DDXXXX, DXXXXX, KILL, monoclonal, Opsonophagocytosis, ORGANISM, Patent Category - Biotechnology, PGA 1, PGA 2, REACT, Schmidt syndrome, That

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Infectious Disease

1 2 3

|

|

|

© 2024. All Rights Reserved. Powered by Inteum